BLAINJECTIONINJECTABLE
Approved
Apr 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
25
Data completeness
5/8 — Partial
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EVENITY (romosozumab-aqqg) is a monoclonal antibody approved by FDA in April 2019 for postmenopausal osteoporosis and related bone loss conditions. It works through a dual mechanism: sclerostin inhibition to stimulate new bone formation while simultaneously reducing bone resorption. The drug is administered as a subcutaneous injection.
$0.001BPart D
PeakProduct is in peak lifecycle stage with modest Part D spending (~$1M in 2023 on 440 claims), suggesting selective market penetration and stable commercial team size.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (25)
Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes
Started Mar 2026
36 enrolled
Osteoporosis, Post-menopausal
Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta
Started Mar 2026
71 enrolled
Osteogenesis Imperfecta
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
Started Apr 2024
106 enrolled
Osteogenesis Imperfecta
A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
Started Oct 2023
100 enrolled
Postmenopausal Osteoporosis
Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa
Started Sep 2021
30 enrolled
Bone Density, LowBone LossAnorexia Nervosa+1 more
Worked on EVENITY at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.